FDA Recalls Tadalafil Tablets Due to Manufacturing Practice Deviations
Accord Healthcare's Tadalafil 5 mg tablets are being recalled due to deviations from current good manufacturing practices identified during an FDA inspection. Approximately 1,113,264 bottles were distributed across the United States, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The recall results from current good manufacturing practice deviations identified during inspection. Per the rubric, this qualifies as a risk-of-harm product where injury has not yet been reported, warranting a High severity score.
Plain-English summary
Accord Healthcare, Inc. is recalling Tadalafil 5 mg tablets due to current good manufacturing practice (CGMP) deviations identified during an FDA inspection. Approximately 1,113,264 bottles with multiple lot codes and expiration dates ranging from April 2023 to August 2025 are affected.
The recall was initiated following an FDA inspection that identified deviations from manufacturing standards. These deviations relate to how the product was manufactured and quality-controlled, though the specific nature of the manufacturing issues was not disclosed in the recall notice.
The affected products were distributed to pharmacies and healthcare facilities throughout the United States, including Puerto Rico, and Canada. Consumers and healthcare providers who have this medication should check their supply against the provided lot numbers and expiration dates. Patients should not discontinue their medication without consulting a healthcare provider; instead, they should contact their pharmacy to determine if they have affected product and obtain a replacement if needed.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2002450
- Exp. Date 4/30/2023
- P2003222
- Exp. Date 5/31/2023
- P2003223
- P2003224
- P2004636
- Exp. Date 8/31/2023
- P2005035
- P2005038
- P2005040
- P2005039
- P2005041
- P2005606
- Exp. Date 9/30/2023
- P2100340
- P2100009
- Exp. Date 12/31/2023
- P2100010
- P2100044
UPCs (5)
- 0316729372107
- 0316729369107
- 0316729370103
- 316729370103
- 316729370165
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27